検索
Nervgen Pharma Ord Shs
NGENウォッチリストに追加
2.120USD
+0.030+1.44%
終値 07/02, 13:00（ET）15分遅れの株価
171.78M時価総額
損失額直近12ヶ月PER
詳細情報 Nervgen Pharma Ord Shs 企業名
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Nervgen Pharma Ord Shsの企業情報
企業コードNGEN
会社名NervGen Pharma Corp
上場日Mar 13, 2019
最高経営責任者「CEO」Rogers (Adam H)
従業員数- -
証券種類Ordinary Share
決算期末- -
本社所在地Suite 1703 - 595 Burrard Street
都市VANCOUVER
証券取引所NASDAQ OMX - NASDAQ BASIC
国Canada
郵便番号V7X 1J1
電話番号16047225361
ウェブサイトhttps://www.nervgen.com/
企業コードNGEN
上場日Mar 13, 2019
最高経営責任者「CEO」Rogers (Adam H)
Nervgen Pharma Ord Shsの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Mr. John Craig Thompson
Mr. John Craig Thompson
Independent Director
Independent Director
--
--
Dr. Adam H. Rogers
Dr. Adam H. Rogers
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Gianni (John) Ruffolo
Mr. Gianni (John) Ruffolo
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
よくある質問
Nervgen Pharma Ord Shsの上位5名の株主は誰ですか？
Nervgen Pharma Ord Shsの上位5名の株主は以下のとおりです。Dr. Randall E. Kaye, M.D.
Nervgen Pharma Ord Shs（NGEN）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Nervgen Pharma Ord Shsの株式を保有している機関は17社あり、保有株式の総市場価値は約350.93Kで、全体の0.44%を占めています。2025Q4と比較して、機関の持ち株は303132.00増加しています。